medical cannabis

The news was trumpeted around the world: Germany, the European Union’s largest economy, surprised the global cannabis industry with the announcement of the legalization of cannabis for restricted recreational use, to be effective April 1. Additional regulations for collective private...

Cannabis businesses in survival mode must identify their core competencies and streamline operations to stay solvent and restore trust.  The legacy cannabis market is in distress. To bring it back from the brink, lenders and operators need transparent evaluations and rapid action to preserve...

Could the future of healthcare be intertwined with cannabis-based medicines? A recent report by Prohibition Partners, a data, media and tech company operating in the cannabis industry, reveals a remarkable 650% surge in clinical trials using cannabis-based medicines to alleviate symptoms...

Brett Hull, Hockey Hall of Famer, now boasts a cannabis strain and dispensary of his own. Together with his former Blues teammates Kelly Chase and Barret Jackman, he opened Hippos dispensary in Missouri in 2021. The launch of the “Brett Hull No. 16" medical marijuana strain and opening...

Innovative Industrial Properties, Inc. (NYSE: IIPR), announced that it has commenced a public offering of 1,000,000 shares of its common stock. IIPR is an internally-managed real estate investment trust (REIT) focused on the acquisition, ownership and management of specialized...

The bullish case for cannabis company Tilray Inc (NASDAQ: TLRY) can no longer be justified after the company's third-quarter earnings report showed stalling momentum in international markets, according to Jefferies. The Tilray Analyst: Owen Bennett downgraded Tilray from Hold to Underperform...

Canadian cannabis giant Canopy Growth Corp (NYSE: CGC) announced a new global brand that will include all of the company's medical operations. What Happened Canopy's new brand, Spectrum Therapeutics, will incorporate the company's ongoing commercial medical and clinical research...

CURE Pharmaceutical Holding Corp (OTC: CURR) said Tuesday it managed to broaden its license from the U.S. Drug Enforcement Administration. The expanded license as an authorized manufacturer of Schedule 1 substances to include both cannabis plant extracts and synthetic cannabidiol (CBD) will allow...

Cowen is taking a more constructive view on Canopy Growth Corp. (NYSE: CGC)'s early lead in the cannabis industry after a meeting with the marijuana company's management. The Analyst Cowen analyst Vivien Azer maintained an Outperform rating on Canopy Growth's Canadian stock ...